Zai Lab HK shares fall to 5-week low on weak Q1 results
** HK shares of Zai Lab 9688.HK drop 7.6% to HK$14.97, lowest since April 1 ** Stock set for biggest one-day pct decline since April 23; top pct loser on Hang Seng Biotech Index .HSBIO, which is down 1.4% ** U.S-listed stock ZLAB.O fell 5.9% on Thursday ** Oncology, immunology, neuroscience, infectious disease-focused biopharma group's Q1 total revenue falls 6% y/y ** Net loss widens to $51 mln from year-ago $48.4 mln net loss ** YTD, HK stock up 12.4%, U.S.-listed shares up 12.1% (Reporting by Donny Kwok) ((donny.kwok@thomsonreuters.com))
Recent news on Zai Lab
See all newsBrief: Zai Lab Agrees To Issue To Investors Aggregate Of 11.3 Million ADSs
Zai Lab's Hong Kong shares hit three-month high on quarterly revenue beat
Brief: U.S. FDA Grants Orphan Drug Designation To Zai Lab’S Dll3-Targeting Adc Zocilurtatug Pelitecan (Zoci) For The Treatment Of Neuroendocrine Carcinomas (Necs)
Brief: Goldman Sachs Group's Long Position In Zai Lab Decreases On May 14, HKEX Filing Shows
Brief: Zai Lab Receives U.S. FDA Fast Track Designation For Zocilurtatug Pelitecan (Zoci)